- Home
- CELU vs PVL Comparison
CELU vs PVL Comparison
Compare CELU & PVL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CELU
- PVL
- Stock Information
- Founded
- CELU 2016
- PVL 2011
- Country
- CELU United States
- PVL United States
- Employees
- CELU N/A
- PVL N/A
- Industry
- CELU Biotechnology: Pharmaceutical Preparations
- PVL Oil & Gas Production
- Sector
- CELU Health Care
- PVL Energy
- Exchange
- CELU Nasdaq
- PVL Nasdaq
- Market Cap
- CELU 42.2M
- PVL N/A
- IPO Year
- CELU N/A
- PVL N/A
- Fundamental
- Price
- CELU $1.63
- PVL $1.56
- Analyst Decision
- CELU
- PVL
- Analyst Count
- CELU 0
- PVL 0
- Target Price
- CELU N/A
- PVL N/A
- AVG Volume (30 Days)
- CELU 102.4K
- PVL 51.9K
- Earning Date
- CELU 12-06-2024
- PVL 01-01-0001
- Dividend Yield
- CELU N/A
- PVL 6.07%
- EPS Growth
- CELU N/A
- PVL N/A
- EPS
- CELU N/A
- PVL 0.09
- Revenue
- CELU $48,200,000.00
- PVL $4,339,313.00
- Revenue This Year
- CELU N/A
- PVL N/A
- Revenue Next Year
- CELU $233.89
- PVL N/A
- P/E Ratio
- CELU N/A
- PVL $18.13
- Revenue Growth
- CELU 225.94
- PVL N/A
- 52 Week Low
- CELU $1.00
- PVL $1.03
- 52 Week High
- CELU $5.69
- PVL $1.96
- Technical
- Relative Strength Index (RSI)
- CELU 46.69
- PVL 58.64
- Support Level
- CELU $1.64
- PVL $1.52
- Resistance Level
- CELU $2.40
- PVL $1.57
- Average True Range (ATR)
- CELU 0.20
- PVL 0.04
- MACD
- CELU 0.01
- PVL -0.00
- Stochastic Oscillator
- CELU 17.20
- PVL 94.90
About CELU Celularity Inc.
Celularity Inc is a clinical-stage biotechnology company developing off-the-shelf placental-derived allogeneic cell therapies including genetically modified and unmodified NK cells, engineered T cells including CAR-T cells, and mesenchymal-like adherent stromal cells, targeting indications across cancer, immunologic, infectious, and degenerative diseases. It manages its operations through an evaluation of three distinct business segments which include Cell Therapy, Degenerative Disease, and bio-banking. The company generates the majority of its revenue from bio-banking segment.